PP

Propanc Biopharma IncOOTC PPCB Stock Report

Last reporting period 31 Dec, 2023

Updated 14 Nov, 2024

Last price

Market cap $B

0

Micro

Exchange

OOTC - OTC

PPCB Stock Analysis

PP

Uncovered

Propanc Biopharma Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0

Dividend yield

Shares outstanding

889.75 B

Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate PRP is a pharmaceutical composition consisting of two pancreatic proenzymes trypsinogen and chymotrypsinogen for treating cancer. PRP is a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. It’s a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP reverses the conversion from an epithelial to a mesenchymal phenotype, reducing the metastatic potential of the tumor. Pancreatic Enzyme Therapy uses natural elements within its organism that could help treat cancer.

View Section: Eyestock Rating